A. Activating natural killer cells and dendritic cells B. Blocking T-cell inhibitory signals C. Providing T-cell costimulatory signals D. I am not sure

A. Tocilizumab, infliximab, and rituximab B. Durvalumab, avelumab, and alemtuzumab C. Nivolumab, pembrolizumab, and cemiplimab-rwlc D. I am not sure

A. Prostate cancer, colon cancer, pancreatic cancer, breast cancer, and myeloma B. Melanoma, renal cancer, non-small cell lung cancer, head and neck cancer, and bladder cancer C. Melanoma, lung cancer, prostate cancer, breast cancer, and myeloma D. I am not sure

A. American Society of Clinical Oncology (ASCO) Value Framework is the only model recommended for use in determining the value of cancer therapies B. While many different value frameworks are available, National Comprehensive Cancer Network (NCCN) Evidence Blocks^™ is the most widely used framework in the health plan arena C. ASCO Value Framework, ESMO Magnitude of Clinical Benefit Scale, and ICER Value Assessment Framework are all considered to be oncology value assessment frameworks, while NCCN Evidence Blocks^™ and MAKCC Drug Abacus are not D. ASCO Value Framework, NCCN Evidence Blocks^™, ESMO Magnitude of Clinical Benefit Scale, ICER Value Assessment Framework, and MSKCC Drug Abacus are all among the oncology value assessment frameworks in current use E. I am not sure

A. Underestimating the treatment costs necessary to achieve maximum benefit B. Underestimating the impact of acute but reversible toxicities C. Underestimating the value of long-term survival and treatment-free survival D. I am not sure